Clinical Trial Update: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 [Phase 1, Phase 2]

View source ↗

Summary

This document updates the KRYSTAL-1 Phase 1/2 trial evaluating Mirati's KRAS G12C inhibitor MRTX849 in patients with KRAS G12C-mutant cancer; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• MRTX849 (sotorasib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Cancer, Metastatic Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING